Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew G Annis

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Oncogene|September 1, 2022
GPNMB: a potent inducer of immunosuppression in cancerAnna-Maria Lazaratos, Matthew G Annis, Peter M Siegel
Oncotargets and Therapy|July 23, 2013
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancerGordana Maric, April An Rose, Matthew G Annis, et al.
Biochimica Et Biophysica Acta|March 5, 2004
There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulumMatthew G Annis, Jeremy A Yethon, Brian Leber, et al.
Molecular & Cellular Proteomics : MCP|February 15, 2015
Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarrayHuiyan Li, Sébastien Bergeron, Matthew G Annis, et al.
Molecular Cell|May 20, 2004
During apoptosis bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondriaPeter K Kim, Matthew G Annis, Paulina J Dlugosz, et al.
Plos One|January 7, 2014
Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerCynthia Guilbert, Matthew G Annis, Zhifeng Dong, et al.
Breast Cancer Research : BCR|August 18, 2025
Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomesMatthew Dankner, Veronique Ouellet, Jakob Lafon, et al.
Molecular and Cellular Biology|March 12, 2008
Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasionJason J Northey, Juliann Chmielecki, Elaine Ngan, et al.
Oncotarget|April 1, 2015
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasisSébastien Tabariès, Matthew G Annis, Brian E Hsu, et al.
Plos One|August 17, 2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic propertiesApril A N Rose, Matthew G Annis, Zhifeng Dong, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Oncogene|September 1, 2022
GPNMB: a potent inducer of immunosuppression in cancerAnna-Maria Lazaratos, Matthew G Annis, Peter M Siegel
Oncotargets and Therapy|July 23, 2013
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancerGordana Maric, April An Rose, Matthew G Annis, et al.
Biochimica Et Biophysica Acta|March 5, 2004
There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulumMatthew G Annis, Jeremy A Yethon, Brian Leber, et al.
Molecular & Cellular Proteomics : MCP|February 15, 2015
Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarrayHuiyan Li, Sébastien Bergeron, Matthew G Annis, et al.
Molecular Cell|May 20, 2004
During apoptosis bcl-2 changes membrane topology at both the endoplasmic reticulum and mitochondriaPeter K Kim, Matthew G Annis, Paulina J Dlugosz, et al.
Plos One|January 7, 2014
Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerCynthia Guilbert, Matthew G Annis, Zhifeng Dong, et al.
Breast Cancer Research : BCR|August 18, 2025
Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomesMatthew Dankner, Veronique Ouellet, Jakob Lafon, et al.
Molecular and Cellular Biology|March 12, 2008
Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasionJason J Northey, Juliann Chmielecki, Elaine Ngan, et al.
Oncotarget|April 1, 2015
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasisSébastien Tabariès, Matthew G Annis, Brian E Hsu, et al.
Plos One|August 17, 2010
ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic propertiesApril A N Rose, Matthew G Annis, Zhifeng Dong, et al.
Pageof 5